TY - JOUR T1 - Long-term safety and tolerability of delamanid-containing regimens in MDR- and XDR-TB patients in a specialised tuberculosis treatment center in Berlin, Germany JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00009-2020 SP - 2000009 AU - Brit Häcker AU - Nicolas Schönfeld AU - David Krieger AU - Ralf Otto-Knapp AU - Norbert Hittel AU - Patricia Pflugmacher AU - Torsten Bauer Y1 - 2020/01/01 UR - http://erj.ersjournals.com/content/early/2020/06/08/13993003.00009-2020.abstract N2 - Drug-resistant tuberculosis (DR-TB) is an ongoing challenge for patients and health care systems. The WHO estimated 484 000 (CI: 417 000–556 000) new multidrug-/rifampicin-resistant tuberculosis (MDR-/RR-TB) cases for 2018 [1]. While new and repurposed drugs show promising results in studies, notified treatment outcomes are still below expectations. Germany as a low incidence country had 5429 newly diagnosed TB cases (incidence rate 6,5/100 000) including 118 patients with MDR-TB and 8 patients with XDR-TB in 2018.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Haecker reports grants from Otsuka, during the conduct of the study.Conflict of interest: Dr. Schönfeld has nothing to disclose.Conflict of interest: Dr. Krieger has nothing to disclose.Conflict of interest: Dr. Otto-Knapp has nothing to disclose.Conflict of interest: Dr. Norbert reports personal fees from Otuska Novel products, during the conduct of the study.Conflict of interest: Dr. Pflugmacher has nothing to disclose.Conflict of interest: Dr. Bauer has nothing to disclose.Dr. Bauer has nothing to disclose. ER -